Vetter, a pharmaceutical service provider specializing in injectable drug manufacturing, recently announced that it will build a new production facility in Saarland, southwestern Germany. This investment in the injectable drug production facility is a crucial milestone in the company's global development strategy, marking its further expansion in the European market.

According to the plan, construction will commence in the second quarter of 2026. The first phase of construction has secured approximately €480 million in funding, and the European Commission has also approved state aid of up to €47 million for the project.

This new injectable drug production base is expected to create around 2,000 jobs in the long term and is scheduled to become operational in 2031. Meanwhile, Vetter recently began constructing a new clinical production base in Des Plaines, Illinois, USA, to strengthen its global service capabilities.

Earlier this year, Vetter made significant progress in sustainability, with its emission reduction targets validated by the Science Based Targets initiative (SBTi) and receiving the EcoVadis Platinum rating. These achievements further solidify its professional reputation in the pharmaceutical services sector.